Bicuspid Aortic Valve Disease With Early Onset Complications: Characteristics And Aortic Outcomes - Selbst, Maximilian A.; Laughlin, Megan K.; Ward, Colin R.; Michelena, Hector; Sabate-Rotes, Anna; Bianco, Lisa; De Backer, Julie; Mosquera, Laura Muiño; Yetman, Anji T.; Bissell, Malenka M; Andreassi, Maria Grazia; Foffa, Ilenia; et al. (medRxiv, 2024)
Bicuspid aortic valve (BAV) is the most common congenital heart malformation in adults but can also cause childhood-onset complications. In multicenter study, we found that adults who experience significant complications of BAV disease before age 30 are distinguished from the majority of BAV cases that manifest after age 50 by a relatively severe clinical course, with higher rates of surgical interventions, more frequent second interventions, and a greater burden of congenital heart malformations. These observations highlight the need for prompt recognition, regular lifelong surveillance, and targeted interventions to address the significant health burdens of patients with early onset BAV complications.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549564/ Funding StatementThis work was supported in part by R01HL137028 (S.K.P.) and R01HL114823 (S.C.B.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Committee for the Protection of Human Subjects at the University of Texas Health Science Center at Houston (HSC-MS-11-0185). All participants signed a written consent form, and study procedures were conducted in compliance with the ethical standards of the relevant national guidelines on human experimentation (HHS regulations 45 CFR part 46) and with the Helsinki Declaration of 1975, as revised in 2008. IRB of the University of Texas Health Science Center at Houston (HSC-MS-11-0185) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.redcap.com BAVBicuspid Aortic ValveHTADheritable thoracic aortic disease